BioInsights - Achieving cost-effective, scalable high-titer AAV production

Achieving cost-effective, scalable high-titer AAV production

Cell & Gene Therapy Insights 2021; 7(9), 1147

10.18609/cgti.2021.152

Published: 30 September 2021
FastFacts
Chao Yan Liu

Watch the video or read the poster to learn:

  • Methods to increase AAV titers, reducing overall production costs
  • Scalable protocols for suspension systems, from shake flask to bioreactor scale
  • How to streamline a helper virus-free triple transfection protocol to simplify workflow

Chao Yan Liu gained an MD from the Hebei Medical University (Hebei, China) and a Master’s degree in Pathology from the Academy of Medical Sciences in Beijing, China. She got her post-doctoral training at the Blood Research Institute, Medical School of Wisconsin, and then became a research assistant professor at the University of Buffalo, New York. After more than 10 years in academic research in the field of cellular biology and immunology, in 2005 she joined the Research and Development department of the former Life Technologies. She has extensive experience in mammalian cell culture, chemically defined medium formulation, and protein expression. In the past 3 years, she and her team have focused on the AAV-Max viral production system and next-generation protein expression system development.